Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of sorafenib when given
together with cetuximab and irinotecan and to see how well they work in treating patients
with advanced or metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to
grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances
to them. Sorafenib and cetuximab may also stop tumor growth by blocking blood flow to the
tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to kill tumor
cells, either by killing the cells or by stopping them from dividing. Giving sorafenib
together with cetuximab and irinotecan may kill more tumor cells